Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-23
2006-05-23
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C546S229000, C546S329000
Reexamination Certificate
active
07049330
ABSTRACT:
This invention relates to compounds which have activity as 5-HT1Aagonists and antagonists which may be useful for the treatment of anxiety, depression, cognitive deficits, and prostate cancer, having the formulawherein: X is a moiety selected from the group of:n is selected from the integers 1 through 5; R1is optionally substituted aryl or mono or bicyclic heteroaryl, with a proviso that heteroaryl is not thiadiazole; R2is H or alkyl; R3is H, COR5, COOR5, and CONR5R6; R4is H, alkyl, alkenyl, alkynyl, aryl, mono or bicyclic heteroaryl, aralkyl, and mono or bicyclic heteroaralkyl, wherein the aryl or heteroaryl groups are optionally substituted; R5and R6are H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, adamantyl, and noradamantyl or R5and R6taken together may form a 5–7 membered azacyclic ring, optionally containing an additional heteroatom selected from O, S, or NR4; when R5or R6are chosen from cycloalkyl or cycloalkenyl, the cyclic group may optionally be substituted at the 1-position with a C1–C3alkyl group;or an optical isomer; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 3717634 (1973-02-01), Wu et al.
patent: 4873331 (1989-10-01), Childers et al.
patent: 4882432 (1989-11-01), Abou-Gharbia et al.
patent: 4988814 (1991-01-01), Abou-Charbia et al.
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5340812 (1994-08-01), Cliffe
patent: 5364849 (1994-11-01), Cliffe
patent: 5486518 (1996-01-01), Yardley et al.
patent: 5519025 (1996-05-01), Yardley et al.
patent: 6469030 (2002-10-01), Farrar et al.
patent: 0 434 561 (1991-06-01), None
patent: 0 512 755 (1994-12-01), None
patent: 0 506 468 (1995-04-01), None
patent: WO 93/03016 (1993-02-01), None
patent: WO 93/11122 (1993-06-01), None
patent: WO 94/21610 (1994-09-01), None
patent: WO 95/33729 (1995-12-01), None
patent: WO 95/33743 (1995-12-01), None
patent: WO 96/01656 (1996-01-01), None
patent: WO 96/16949 (1996-06-01), None
patent: WO 97/40038 (1997-10-01), None
patent: WO 99/65887 (1999-12-01), None
Cantrell et al. “Preparation and formulation . . . ” CA 118:212896 (1993).
Custers et al. “Vesamicol and some . . . ” Ca 128:112391 (1997).
Bohlen et al. “Application of opiate antagonist and . . . ” CA 128:84404 (1998).
Efange et al. “Synthesis and biological . . . ” CA 135:133963 (2001) 10/340087.
Rasmussen et al., Annual Rpts. In Med. Chem., vol. 30, 1-9 (1995).
Glennon, R.A., Drug Development Res., 26(3), 251-274 (1992).
Sleight, A.J. et al., Naunyn-Schmiedeberg's Archives of Pharmacology, 343, 109-116 (1991).
Cliffe, I.A. et al., Drugs of the Future, 18(7), 631-642 (1993).
Nelson, D.L., Pharmacology Biochemistry & Behavior, 40, 1041-1051 (1991).
Glennon, R. et al., J. Med. Chem. 32(8), 1921-1926 (1989).
Glennon, R. et al., Drug Development Research, 16(2/04), 335-343 (1989).
Kuipers et al., J. Med. Chem., 1942-1954 (1995).
Custers, Franciscus et al., European Journal of Pharmacology, 338, 177-183 (1997).
Childers Wayne E.
Kelly Michael G.
Palmer Yvette L.
Podlesny Edward J.
Chang Celia
Hild Kimberly R.
Wyeth
LandOfFree
Cycloalkyl-substituted aryl-piperazines, piperidines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl-substituted aryl-piperazines, piperidines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl-substituted aryl-piperazines, piperidines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542883